• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The mechanism of allo-grafted cell Rejection by Allo-Induced Macrophages

Research Project

Project/Area Number 22791504
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeSingle-year Grants
Research Field Urology
Research InstitutionOsaka Medical College

Principal Investigator

NOMI Hayahito  大阪医科大学, 医学部, 講師 (80418938)

Project Period (FY) 2010-04-01 – 2014-03-31
Project Status Completed (Fiscal Year 2013)
Budget Amount *help
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Keywordsアロマクロファージ / 急性拒絶反応 / 免疫寛容 / 同異種系移植 / マウス / マクロファージ / effector / 同種異系移植 / アロ活性化マクロファージ / 拒絶反応 / NK細胞 / 同種移植 / 既活性化マクロファージ / AIM
Research Abstract

The effector cells of allo-rejection has been to be killer T cells (CTL) or NK cells. However, several events which CTL cannot producing some allograft rejections have also been reported. We have shown that allo-activated macrophages are the major effector of some allograft rejections. We confirmed that the allo-cytotoxic activity is higher in Mac-1 positive fraction, which is a surface marker of macrophage, than in NK1.1-positive fraction of effector cells through the rejection of allo-grafted Meth A fibrosarcoma cells grafted into the abdominal cavity of mice. In addition, to obtain the results suggest that activated macrophage is the effector cell from the fact that the cytotoxic activity of peritoneal infiltration cell of allograft after slightly higher with antibodies against Meth A cells, in vitro.

Report

(5 results)
  • 2013 Annual Research Report   Final Research Report ( PDF )
  • 2012 Annual Research Report
  • 2011 Annual Research Report
  • 2010 Annual Research Report
  • Research Products

    (6 results)

All 2013 2012

All Presentation (6 results)

  • [Presentation] 腎移植の概要と最近の動向について大腎協2013

    • Author(s)
      能見 勇人
    • Organizer
      移植部第12回臓器移植学習会
    • Place of Presentation
      大阪産業会館
    • Year and Date
      2013-09-01
    • Related Report
      2013 Final Research Report
  • [Presentation] 免疫賦活療法から分子標的に切り替え腎細胞癌多発肺転移後5年以上病勢コントロールできている症例2013

    • Author(s)
      能見 勇人
    • Organizer
      FOCUS2013
    • Place of Presentation
      東京コンファレンスセンター品川
    • Year and Date
      2013-07-06
    • Related Report
      2013 Final Research Report
  • [Presentation] 腎移植の概要と最近の動向について2013

    • Author(s)
      能見勇人
    • Organizer
      大腎協移植部第12回臓器移植学習会
    • Place of Presentation
      大阪産業創造館(大阪市中央区)
    • Related Report
      2013 Annual Research Report
  • [Presentation] "A Case of BK Virus Nephropathy; Urinary NAG-index Was Useful to Examine the2013

    • Author(s)
      能見勇人
    • Organizer
      The 13th Congress of the Asian Society of Transplantation(CAST2013)
    • Place of Presentation
      国立京都国際会館(京都市左京区)
    • Related Report
      2013 Annual Research Report
  • [Presentation] 免疫賦活療法から分子標的製剤療法に切り替え腎細胞癌多発肺転移後4年以上の生存中の2例の検討2012

    • Author(s)
      能見 勇人, 稲元 輝生, 高原 健, 西田 剛, 南 幸一郎, 光野 絢子, 上原 博史, 小村 和正, 右梅 貴信, 東 治人
    • Organizer
      第62回日本泌尿器科学会中部総会
    • Year and Date
      2012-11-02
    • Related Report
      2013 Final Research Report
  • [Presentation] 免疫賦活療法から分子標的製剤療法に切り替え腎細胞癌多発肺転移後4年以上の生存中の2例の検討2012

    • Author(s)
      能見 勇人、稲元輝生、高原 健、西田 剛、南 幸一郎、光野絢子、上原博史、小村和正、右梅貴信、東 治人
    • Organizer
      第62回日本泌尿器科学会中部総会
    • Place of Presentation
      富山国際会議場(富山県)
    • Related Report
      2012 Annual Research Report

URL: 

Published: 2010-08-23   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi